The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 483-489

  Shi, Zhi ^a,b   Parmar, Smitaben ^a   Peng, Xing Xiang ^a   Shen, Tong ^a   Robey, Robert W ^c   Bates, Susan E ^c   Fu, Li Wu ^b   Shao, Yining ^a   Chen, Yang Min ^a   Zang, Feiyang ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABCG2; AG1478; Erlotinib; Multidrug resistance

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; ERLOTINIB; FLAVOPIRIDOL; FUMITREMORGIN C; MITOXANTRONE; OSI 744; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR PROTEIN; TYRPHOSTIN;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG SENSITIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; MULTIDRUG RESISTANCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; QUINAZOLINES; TYRPHOSTINS;

EID: 62849124784     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000248     Document Type: Article

References (37)

1. Doyle LA and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358, 2003.
2. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T and Sugimoto Y: Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 97: 626-630, 2002.
3. Krishnamurthy P and Schuetz JD: Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46: 381-410, 2006.
4. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC and Kaufmann SH: The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 61: 739-748, 2001.
5. Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ and Stewart CF: Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 66: 4802-4807, 2006.
6. Robey RW, Polgar O, Deeken J, To KW and Bates SE: ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26: 39-57, 2007.
7. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD and Sorrentino BP: Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 99: 12339-12344, 2002.
8. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T and Greenberger LM: Reversal of a novel multi-drug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 58: 5850-5858, 1998.
9. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ and Schinkel AH: Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1: 417-425, 2002.
10. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H and Baer MR: Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11:2320-2326, 2005.
11. de Bruin M, Miyake K, Litman T, Robey R and Bates SE: Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146: 117-126, 1999.
12. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P and Bates SE: Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64: 1242-1246, 2004.
13. Minderman H, O'Loughlin KL, Pendyala L and Baer MR: VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10: 1826-1834, 2004.
14. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G and Nooter K: Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 2940-2942, 2004.
15. Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, Szabo K, Homolya L, Varadi A, Buday L, Keri G, Nemet K and Sarkadi B: Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65: 1770-1777, 2005.
16. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E and Traxler P: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64: 2333-2337, 2004.
17. + cells and is inhibited by imatinib mesylate. Blood 108: 1370-1373, 2006.
18. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H and Kohno S: Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ ABCG2-mediated drug resistance. Cancer Res 65: 1541-1546, 2005.
19. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y and Sugimoto Y: Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3: 1119-1125, 2004.
20. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD and Bates SE: Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7: 145-152, 2001.
21. Shi Z, Jain S, Kim IW, Peng XX, Abraham I, Youssef DT, Fu LW, El Sayed K, Ambudkar SV and Chen ZS: Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Cancer Sci 98: 1373-1380, 2007.
22. Shi Z, Liang YJ, Chen ZS, Wang XH, Ding Y, Chen LM and Fu LW: Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. Oncol Rep 17: 969-976, 2007.
23. Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, Chen LM, Yang XP and Fu LW: Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 5: 39-47, 2006.
24. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ III, Gilbertson R, Germain GS, Harwood FC and Houghton PJ: Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64: 7491-7499, 2004.
25. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J and Yang PC: Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65: 6943-6949, 2005.
26. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M and Bates SE: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61: 6635-6639, 2001.
27. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS and Bates SE: Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89: 1971-1978, 2003.
28. Grant S, Qiao L and Dent P: Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 7: D376-D389, 2002.
29. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16, 2006.
30. Cascone T, Morelli MP and Ciardiello F: Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. Ann Oncol 17 (Suppl 2): 46-48, 2006.
31. Grunwald V and Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851-867, 2003.
32. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, Takemura M, Yabuuchi H, Soda H and Kohno S: Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49: 337-343, 2005.
33. Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Volker U and Kroemer HK: Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 34: 524-533, 2006.
34. Allen JD and Schinkel AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ ABCG2). Mol Cancer Ther 1: 427-434, 2002.
35. Zhuang Y, Fraga CH, Hubbard KE, HagedornN, Panetta JC, Waters CM and Stewart CF: Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res 66: 11305-11313, 2006.
36. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A and Baker SD: Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98: 1739-1742, 2006.
37. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M and Baker SD: Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6: 432-438, 2007.